CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-07 | SUN ANTHONY Y President & CEO | Purchase | +888 | $18.00 | $16K | 2,146,568 |
| 2020-04-07 | Epperly Melissa B, Chief Financial Officer | Grant or award | +147,394 | 277,529 | ||
| 2020-04-07 | SUN ANTHONY Y President & CEO | Grant or award | +303,392 | 2,145,680 | ||
| 2020-04-07 | Johnson David Michael Director | Grant or award | +51,587 | 110,648 | ||
| 2020-04-07 | Gallagher Cam Director | Grant or award | +73,478 | 489,143 | ||
| 2020-04-07 | Bunker Kevin D. Chief Operating Officer | Grant or award | +99,246 | 544,650 | ||
| 2020-04-07 | VIKING GLOBAL INVESTORS LP 10% owner | Purchase | +725,000 | $18.00 | $13.1M | 4,443,284 |
Page 32 of 32 · 627 trades